Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-11 DOI:10.1080/14737140.2024.2362178

Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti

{"title":"Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.","authors":"Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti","doi":"10.1080/14737140.2024.2362178","DOIUrl":null,"url":null,"abstract":"Introduction: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.Areas covered: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.Expert opinion: Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"649-655"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2362178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.

Areas covered: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.

Expert opinion: Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

复发性卵巢癌的 Relacorilant：临床证据与未来展望。

简介Relacorilant（CORT125134，Corcept Therapeutics公司）是一种选择性糖皮质激素受体调节剂，可逆转糖皮质激素介导的抗凋亡效应，恢复上皮卵巢癌细胞对紫杉类药物的化疗敏感性。鉴于这些临床前研究结果，relacorilant 目前正在与纳布-紫杉醇（nab-paclitaxel）联用治疗铂类耐药卵巢癌的临床试验中进行研究：分析和讨论了已发表的relacorilant抗肿瘤活性的临床前和临床证据。还报告了在clincaltrials.gov上注册的正在进行的临床试验。综述旨在总结relacorilant的现状、作用机制、已发表和正在进行的试验，以及其安全性和有效性：专家观点：Relacorilant与纳布-紫杉醇联用可能是治疗铂类耐药卵巢癌患者的一种有前途的策略。在临床疗效方面取得初步积极成果后，目前正在进行一项随机III期试验，以证实已发表的II期研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.